Telix Pharmaceuticals Launches TMS Yokohama: A Milestone in Radiopharmaceutical Access for Japan

Telix Pharmaceuticals Launches First Cyclotron Facility in Asia Pacific, Enhancing Cancer Care in Japan

Yokohama, Japan – In a significant advancement for cancer diagnostics and treatment, Telix Pharmaceuticals Limited has officially opened its first cyclotron facility in the Asia Pacific region, Telix Manufacturing Solutions (TMS) Yokohama. This landmark event, held on November 21, 2025, marks a pivotal moment for the company and the Japanese healthcare landscape.

The new facility aims to improve access to radiopharmaceuticals for patients in Japan, starting with the clinical supply of TLX250-CDx, an innovative imaging candidate for kidney cancer. Future plans include the provision of precision diagnostics and therapies for prostate and brain cancers, pending regulatory approvals.

To commemorate the opening, a lecture titled “Trends and Challenges for the Future of Nuclear Medicine” was delivered by Professor Jun Hatazawa, Vice President of the Japan Isotope Association and a leading figure in cancer therapy research at Osaka University. His insights highlighted the evolving landscape of nuclear medicine and the critical role of facilities like TMS in advancing patient care.

Raphael Ortiz, CEO of International Business and President of Telix Japan, emphasized the importance of this facility in meeting the growing demand for radiopharmaceuticals in Japan, the world’s second-largest nuclear medicine market. “Today demonstrates our commitment to the Japanese community, to scientific excellence, and to the well-being of patients throughout the region,” Ortiz stated.

TMS Yokohama is part of a global network of 39 manufacturing and distribution facilities across five continents, enabling Telix to deliver both commercial and clinical doses to patients worldwide. The facility will leverage advanced technologies, including the ARTMS QUANTM Irradiation System® (QIS®), to enhance isotope production and radiopharmaceutical manufacturing.

Telix Pharmaceuticals, headquartered in Melbourne, Australia, is dedicated to developing and commercializing therapeutic and diagnostic radiopharmaceuticals. With operations spanning multiple countries, including the United States, United Kingdom, and Brazil, Telix is committed to addressing significant unmet medical needs in oncology and rare diseases.

As the company continues to expand its footprint in the Asia Pacific region, the opening of TMS Yokohama represents a crucial step in enhancing cancer care and improving patient outcomes in Japan and beyond.

For more information about Telix and its innovative solutions, visit Telix Pharmaceuticals.